Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A Plus Biotechnology CoTPE:6918 72 EV-to-EBIT is 9.33 as of Aug. 20, 2026, which is 22% below its 10-year median of 12.02. GuruFocus rates TPE:6918 with a GF Score™ of 72/100 and a GF Value™ of NT$86.57 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 472 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks better than 79.03% on this metric.
The historical rank and industry rank for A Plus Biotechnology Co's EV-to-EBIT or its related term are showing as below:
TPE:6918'
s EV-to-EBIT Range Over the Past 10 Years
Min: -222.26 Med: 12.02 Max: 78.04
Current: 9.33
During the past 7 years, the highest EV-to-EBIT of A Plus Biotechnology Co was 78.04. The lowest was -222.26. And the median was 12.02.
TPE:6918's EV-to-EBIT is ranked better than 79.03% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.665
vs TPE:6918: 9.33
A Plus Biotechnology Co (TPE:6918) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
A Plus Biotechnology Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$2,153.5 Mil.
A Plus Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$237.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Plus Biotechnology Co EV-to-EBIT Related Terms
A Plus Biotechnology Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, A Plus Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's EV-to-EBIT falls into.
A Plus Biotechnology Co's current Enterprise Value is NT$2,211.4 Mil.
A Plus Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$237.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Plus Biotechnology Co (TPE:6918) has a EV-to-EBIT of 9.33 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on A Plus Biotechnology Co and its competitors. This is 22% below median its historical median of 12.02. According to the industry distribution chart, A Plus Biotechnology Co ranks #99 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is A Plus Biotechnology Co's EV-to-EBIT too high?
A Plus Biotechnology Co's current EV-to-EBIT of 9.33 is 22% below median its 10-year median of 12.02. The Medical Devices & Instruments industry median EV-to-EBIT is 19.67. A Plus Biotechnology Co's value of 9.33 is 52.6% below this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #99 out of 472 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, A Plus Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #99 out of 472 companies for EV-to-EBIT. This places A Plus Biotechnology Co in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 19.67. A Plus Biotechnology Co's value of 9.33 is 52.6% below this benchmark. While the company's 10-year median is 12.02 vs. the industry median of 19.67, A Plus Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.67, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current EV-to-EBIT of 9.33 is 52.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current EV-to-EBIT is 9.33, which is 22% below median its own 10-year median of 12.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$86.57, compared to a current price of NT$74.00 — trading 14.5% below its estimated fair value. The current EV-to-EBIT is 9.33, which is 22% below median its 10-year median of 12.02 and 52.6% below the Medical Devices & Instruments industry median of 19.67. A Plus Biotechnology Co's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current EV-to-EBIT is 9.33 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$74.00 is trading 14.5% below its estimated GF Value™ of NT$86.57.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
EV-to-EBIT: 9.33 (22% below median its 10-year median of 12.02)
GF Value™: NT$86.57 vs. price of NT$74.00 (14.5% below fair value)
Industry Position: 52.6% below the Medical Devices & Instruments median (#99 of 472)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
72GF Score
Get the complete analysis for TPE:6918
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
